- Home
- GSIW vs RDHL Comparison
GSIW vs RDHL Comparison
Compare GSIW & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | RDHL |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 4.6M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GSIW | RDHL |
|---|---|---|
| Price | $23.92 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 630.4K | 25.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.86 |
| 52 Week High | $36.90 | $3.31 |
Technical Indicators
Market Signals| Indicator | GSIW | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 72.98 | 31.63 |
| Support Level | $0.11 | N/A |
| Resistance Level | N/A | $1.07 |
| Average True Range (ATR) | 3.30 | 0.05 |
| MACD | 2.78 | -0.00 |
| Stochastic Oscillator | 59.25 | 2.79 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.